INCANNEX HEALTHCARE INC (IXHL) Fundamental Analysis & Valuation

NASDAQ:IXHL • US45333F2083

Current stock price

2.87 USD
-0.2 (-6.51%)
Last:

This IXHL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. IXHL Profitability Analysis

1.1 Basic Checks

  • IXHL had negative earnings in the past year.
  • In the past year IXHL has reported a negative cash flow from operations.
  • In the past 5 years IXHL always reported negative net income.
  • In the past 5 years IXHL always reported negative operating cash flow.
IXHL Yearly Net Income VS EBIT VS OCF VS FCFIXHL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M -40M

1.2 Ratios

  • IXHL has a Return On Assets of -64.66%. This is in the lower half of the industry: IXHL underperforms 67.88% of its industry peers.
  • IXHL's Return On Equity of -66.07% is in line compared to the rest of the industry. IXHL outperforms 43.52% of its industry peers.
Industry RankSector Rank
ROA -64.66%
ROE -66.07%
ROIC N/A
ROA(3y)-180.94%
ROA(5y)-141.08%
ROE(3y)-249.71%
ROE(5y)-184.94%
ROIC(3y)N/A
ROIC(5y)N/A
IXHL Yearly ROA, ROE, ROICIXHL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5K 10K

1.3 Margins

  • IXHL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IXHL Yearly Profit, Operating, Gross MarginsIXHL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100K -200K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. IXHL Health Analysis

2.1 Basic Checks

  • IXHL does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, IXHL has more shares outstanding
  • Compared to 5 years ago, IXHL has less shares outstanding
  • There is no outstanding debt for IXHL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IXHL Yearly Shares OutstandingIXHL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
IXHL Yearly Total Debt VS Total AssetsIXHL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M

2.2 Solvency

  • IXHL has an Altman-Z score of 12.91. This indicates that IXHL is financially healthy and has little risk of bankruptcy at the moment.
  • IXHL's Altman-Z score of 12.91 is amongst the best of the industry. IXHL outperforms 87.05% of its industry peers.
  • There is no outstanding debt for IXHL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 12.91
ROIC/WACCN/A
WACC9.88%
IXHL Yearly LT Debt VS Equity VS FCFIXHL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M 20M

2.3 Liquidity

  • IXHL has a Current Ratio of 48.27. This indicates that IXHL is financially healthy and has no problem in meeting its short term obligations.
  • IXHL's Current ratio of 48.27 is amongst the best of the industry. IXHL outperforms 98.96% of its industry peers.
  • A Quick Ratio of 48.27 indicates that IXHL has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 48.27, IXHL belongs to the top of the industry, outperforming 98.96% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 48.27
Quick Ratio 48.27
IXHL Yearly Current Assets VS Current LiabilitesIXHL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. IXHL Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 55.63% over the past year.
  • Looking at the last year, IXHL shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
  • Measured over the past years, IXHL shows a very negative growth in Revenue. The Revenue has been decreasing by -31.02% on average per year.
EPS 1Y (TTM)55.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.79%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-46.82%
Revenue growth 5Y-31.02%
Sales Q2Q%-100%

3.2 Future

  • The Earnings Per Share is expected to grow by 41.47% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 1900.01% on average over the next years. This is a very strong growth
EPS Next Y99.78%
EPS Next 2Y41.47%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y1900.01%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IXHL Yearly Revenue VS EstimatesIXHL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2024 2025 2027 20M 40M 60M
IXHL Yearly EPS VS EstimatesIXHL Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 0 -200 -400 -600 -800

More info and screens

Find the best growth stocksShow best growing peers

4

4. IXHL Valuation Analysis

4.1 Price/Earnings Ratio

  • IXHL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • The Price/Forward Earnings ratio is 2.21, which indicates a rather cheap valuation of IXHL.
  • 97.93% of the companies in the same industry are more expensive than IXHL, based on the Price/Forward Earnings ratio.
  • IXHL is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.70, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 2.21
IXHL Price Earnings VS Forward Price EarningsIXHL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IXHL Per share dataIXHL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -50 -100 -150 -200 -250

4.3 Compensation for Growth

  • IXHL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • IXHL's earnings are expected to grow with 41.47% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.47%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IXHL Dividend Analysis

5.1 Amount

  • No dividends for IXHL!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IXHL Fundamentals: All Metrics, Ratios and Statistics

INCANNEX HEALTHCARE INC

NASDAQ:IXHL (3/24/2026, 3:25:03 PM)

2.87

-0.2 (-6.51%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-13
Earnings (Next)05-13
Inst Owners3.37%
Inst Owner Change149.46%
Ins Owners12.36%
Ins Owner Change91.78%
Market Cap40.09M
Revenue(TTM)N/A
Net Income(TTM)-48.50M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short Ratio0.12
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)36.5%
Min EPS beat(2)36.5%
Max EPS beat(2)36.5%
EPS beat(4)3
Avg EPS beat(4)-205.68%
Min EPS beat(4)-978.6%
Max EPS beat(4)82.87%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)-2900%
EPS NQ rev (3m)-2900%
EPS NY rev (1m)-2900%
EPS NY rev (3m)-2900%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 2.21
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.55
P/tB 0.55
EV/EBITDA N/A
EPS(TTM)-255.48
EYN/A
EPS(NY)1.3
Fwd EY45.15%
FCF(TTM)-1.32
FCFYN/A
OCF(TTM)-1.32
OCFYN/A
SpS0
BVpS5.25
TBVpS5.25
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -64.66%
ROE -66.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-180.94%
ROA(5y)-141.08%
ROE(3y)-249.71%
ROE(5y)-184.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 48.27
Quick Ratio 48.27
Altman-Z 12.91
F-Score4
WACC9.88%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)55.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.79%
EPS Next Y99.78%
EPS Next 2Y41.47%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3Y-46.82%
Revenue growth 5Y-31.02%
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y1900.01%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y7.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year32.24%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-35.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-40.24%
OCF growth 3YN/A
OCF growth 5YN/A

INCANNEX HEALTHCARE INC / IXHL Fundamental Analysis FAQ

What is the ChartMill fundamental rating of INCANNEX HEALTHCARE INC (IXHL) stock?

ChartMill assigns a fundamental rating of 4 / 10 to IXHL.


Can you provide the valuation status for INCANNEX HEALTHCARE INC?

ChartMill assigns a valuation rating of 4 / 10 to INCANNEX HEALTHCARE INC (IXHL). This can be considered as Fairly Valued.


What is the profitability of IXHL stock?

INCANNEX HEALTHCARE INC (IXHL) has a profitability rating of 0 / 10.